Cargando…

Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells

Enzalutamide is a second-generation androgen receptor (AR) antagonist for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Unfortunately, AR dysfunction means that resistance to enzalutamide will eventually develop. Thus, novel agents are urgently needed to treat this devast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Yangyang, Huang, Weiwei, Liu, Jiakuan, Liu, Dandan, Cui, Yangyan, Huang, Ruimin, Yan, Jun, Lei, Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479278/ https://www.ncbi.nlm.nih.gov/pubmed/28638477 http://dx.doi.org/10.7150/thno.17852

Ejemplares similares

Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer
por: Thaper, Daksh, et al.
Publicado: (2018)

A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
por: He, Yundong, et al.
Publicado: (2021)

Triptolide Inhibits the Proliferation of Prostate Cancer Cells and Down-Regulates SUMO-Specific Protease 1 Expression
por: Huang, Weiwei, et al.
Publicado: (2012)

Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
por: Li, Qiuhui, et al.
Publicado: (2018)

Triptolide inhibits cell proliferation and tumorigenicity of human neuroblastoma cells
por: YAN, XIAOMIN, et al.
Publicado: (2015)

The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer
por: Zheng, Zeyuan, et al.
Publicado: (2022)

LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance
por: Zhang, Boya, et al.
Publicado: (2021)

Triptolide induces protective autophagy through activation of the CaMKKβ-AMPK signaling pathway in prostate cancer cells
por: Zhao, Fei, et al.
Publicado: (2015)

Identification of hexosamine biosynthesis pathway as a novel prognostic signature and its correlation with immune infiltration in bladder cancer
por: Cui, Yangyan, et al.
Publicado: (2022)

Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC
por: White, Ralph E., et al.
Publicado: (2023)

Pao Pereira extract suppresses benign prostatic hyperplasia by inhibiting inflammation-associated NFκB signaling
por: Dong, Yu, et al.
Publicado: (2020)

Inhibiting CBP Decreases AR Expression and Inhibits Proliferation in Benign Prostate Epithelial Cells
por: Tang, Xingxing, et al.
Publicado: (2023)

Triptolide Induces Growth Inhibition and Apoptosis of Human Laryngocarcinoma Cells by Enhancing p53 Activities and Suppressing E6-Mediated p53 Degradation
por: Zhao, Fei, et al.
Publicado: (2013)

Aspalathus linearis suppresses cell survival and proliferation of enzalutamide-resistant prostate cancer cells via inhibition of c-Myc and stability of androgen receptor
por: Wang, Bi-Juan, et al.
Publicado: (2022)

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
por: Gurioli, Giorgia, et al.
Publicado: (2020)

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
por: Salvi, Samanta, et al.
Publicado: (2016)

Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells
por: Sarwar, Martuza, et al.
Publicado: (2016)

Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation
por: Simon, Iris, et al.
Publicado: (2021)

Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells
por: Khurana, Namrata, et al.
Publicado: (2020)

Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer
por: Shiota, Masaki, et al.
Publicado: (2015)

Baicalein suppresses the androgen receptor (AR)-mediated prostate cancer progression via inhibiting the AR N-C dimerization and AR-coactivators interaction
por: Xu, Defeng, et al.
Publicado: (2017)

SIRT7 depletion inhibits cell proliferation and androgen-induced autophagy by suppressing the AR signaling in prostate cancer
por: Ding, Mao, et al.
Publicado: (2020)

HC-1119, a deuterated Enzalutamide, inhibits Migration, Invasion and Metastasis of the AR-positive triple-negative breast Cancer cells
por: Wu, Xuehong, et al.
Publicado: (2022)

Rauwolfia vomitoria extract suppresses benign prostatic hyperplasia by inducing autophagic apoptosis through endoplasmic reticulum stress
por: Huang, Guifang, et al.
Publicado: (2022)

RETRACTED ARTICLE: Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC
por: Zhang, Boya, et al.
Publicado: (2021)

Retraction Note: Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC
por: Zhang, Boya, et al.
Publicado: (2023)

Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide
por: Xia, Xiaohong, et al.
Publicado: (2019)

Molecular determinants for enzalutamide-induced transcription in prostate cancer
por: Yuan, Fuwen, et al.
Publicado: (2019)

Pao Pereira Extract Attenuates Testosterone-Induced Benign Prostatic Hyperplasia in Rats by inhibiting 5α-Reductase
por: Liu, Jiakuan, et al.
Publicado: (2019)

Inhibition of Serum Response Factor Improves Response to Enzalutamide in Prostate Cancer
por: Watson, R. William, et al.
Publicado: (2020)

Ganoderma tsugae Inhibits the SREBP-1/AR Axis Leading to Suppression of Cell Growth and Activation of Apoptosis in Prostate Cancer Cells
por: Huang, Shih-Yin, et al.
Publicado: (2018)

Triptolide Promotes Senescence of Prostate Cancer Cells Through Histone Methylation and Heterochromatin Formation
por: Tamgue, Ousman, et al.
Publicado: (2017)

Triptolide Suppresses Glomerular Mesangial Cell Proliferation in Diabetic Nephropathy Is Associated with Inhibition of PDK1/Akt/mTOR Pathway
por: Han, Fei, et al.
Publicado: (2017)

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer
por: Culig, Zoran
Publicado: (2017)

Molecular mechanisms of enzalutamide resistance in prostate cancer
por: Blatt, Eliot B., et al.
Publicado: (2019)

Inhibition of Rac1 reverses enzalutamide resistance in castration-resistant prostate cancer
por: Chen, Xiaoliang, et al.
Publicado: (2020)

Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer
por: Chou, Fu-Ju, et al.
Publicado: (2020)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
por: Attard, Gerhardt, et al.
Publicado: (2018)

Enzalutamide-resistant related lncRNA NONHSAT210528 promotes the proliferation and invasion of prostate cancer
por: Ye, Chen, et al.
Publicado: (2022)

The MYC axis in advanced prostate cancer is impacted through concurrent targeting of ERβ and AR using a novel ERβ-selective ligand alongside Enzalutamide
por: Gray, Jaimie S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d72tqc08nmq9gg9r792r0i4tbs